137 related articles for article (PubMed ID: 36136314)
1. Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.
Strohbehn GW; Holleman R; Burns J; Klamerus ML; Kelley MJ; Kerr EA; Ramnath N; Hofer TP
JAMA Oncol; 2022 Nov; 8(11):1663-1667. PubMed ID: 36136314
[TBL] [Abstract][Full Text] [Related]
2. Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.
Bryant AK; Lewy JR; Bressler RD; Chopra Z; Gyori DJ; Bazzell BG; Moeller JA; Jacobson SI; Fendrick AM; Kerr EA; Ramnath N; Green MD; Hofer TP; Vaishnav P; Strohbehn GW
Lancet Oncol; 2024 Jun; 25(6):802-810. PubMed ID: 38821085
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
5. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.
Sehgal K; Bulumulle A; Brody H; Gill RR; Macherla S; Qilleri A; McDonald DC; Cherry CR; Shea M; Huberman MS; VanderLaan PA; Weiss GJ; Walker PR; Costa DB; Rangachari D
Clin Lung Cancer; 2021 May; 22(3):e379-e389. PubMed ID: 32653295
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
Hijmering-Kappelle LBM; Hiltermann TJN; Bensch F
Clin Lung Cancer; 2022 Mar; 23(2):143-150. PubMed ID: 35034861
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
8. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
9. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.
Jones L; Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2022 Nov; 29(11):8686-8692. PubMed ID: 36421338
[TBL] [Abstract][Full Text] [Related]
10. An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.
Moffat GT; Hanna L; Hopman W; Fung AS; Gaudreau PO
Immunotherapy; 2023 Aug; 15(12):921-932. PubMed ID: 37431608
[TBL] [Abstract][Full Text] [Related]
11. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic.
Ksienski D; Gupta S; Truong PT; Bone J; Chan A; Alex D; Hart J; Pollock P; Patterson T; Clarkson M; Dissanayake D; Sonke E; Lesperance M
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2951-2961. PubMed ID: 35834010
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
14. Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer.
Popat S; Liu SV; Scheuer N; Gupta A; Hsu GG; Ramagopalan SV; Griesinger F; Subbiah V
JAMA Netw Open; 2022 May; 5(5):e2214046. PubMed ID: 35612853
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
16. Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors.
Goldstein DA; Ginsberg GM; Hofnung-Gabbay D; De Abreu Lourenco R; Loong HH; Goh BC; Chan KKW; Di Maio M; Perrone F; Hall PS; Zer A; Rosenbaum E
JAMA Netw Open; 2023 Feb; 6(2):e230490. PubMed ID: 36821111
[TBL] [Abstract][Full Text] [Related]
17. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
18. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: A population-based cohort study.
Murteira R; Borges FC; Mendes GP; Ramos C; Ramos A; Soares P; Furtado C; Miranda A; da Costa FA;
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1295-1302. PubMed ID: 32844487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]